Vigil Neuroscience Inc VIGL:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 03/28/24 EDT
3.41UNCH (UNCH)
Volume
2,075
Close
3.41UNCH (UNCH)
Volume
77,299
52 week range
2.53 - 11.11
Loading...
  • Open3.22
  • Day High3.41
  • Day Low3.19
  • Prev Close3.20
  • 52 Week High11.11
  • 52 Week High Date06/20/23
  • 52 Week Low2.53
  • 52 Week Low Date02/05/24

Key Stats

  • Market Cap122.342M
  • Shares Out35.88M
  • 10 Day Average Volume0.15M
  • Dividend-
  • Dividend Yield-
  • Beta1.81
  • YTD % Change0.89

KEY STATS

  • Open3.22
  • Day High3.41
  • Day Low3.19
  • Prev Close3.20
  • 52 Week High11.11
  • 52 Week High Date06/20/23
  • 52 Week Low2.53
  • 52 Week Low Date02/05/24
  • Market Cap122.342M
  • Shares Out35.88M
  • 10 Day Average Volume0.15M
  • Dividend-
  • Dividend Yield-
  • Beta1.81
  • YTD % Change0.89

RATIOS/PROFITABILITY

  • EPS (TTM)-2.13
  • P/E (TTM)-1.60
  • Fwd P/E (NTM)-1.52
  • EBITDA (TTM)-88.467M
  • ROE (TTM)-54.13%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/11/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Vigil Neuroscience Inc

 

Profile

MORE
Vigil Neuroscience, Inc. is a clinical-stage biotechnology company. It is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its VGL101 product is a fully...
Bruce Booth Ph.D.
Independent Chairman of the Board
Ivana Magovcevic-liebisch J.D., Ph.D.
President, Chief Executive Officer, Director
Jennifer Ziolkowski CPA
Chief Financial Officer
Christopher Verni J.D.
General Counsel
Address
100 Forge Road, Suite 700
Watertown, MA
02472
United States

Top Peers

SYMBOLLASTCHG%CHG
OTLK
Outlook Therapeutics Inc
11.94UNCHUNCH
BLRX
BioLine RX Ltd
1.12UNCHUNCH
ANTX
AN2 Therapeutics Inc
3.25UNCHUNCH
CVM
CEL-SCI Corp
1.91UNCHUNCH
VINC
Vincerx Pharma Inc
5.06UNCHUNCH